Compare Apple Inc (AAPL) vs Becton Dickinson and Co (BDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Apple Inc vs Becton Dickinson and Co — how do they compare? Apple Inc trades at $304.36 (market cap $4.50T), while Becton Dickinson and Co trades at $181.28 (market cap $48.93B). The key difference: Apple Inc is far larger — about 92× Becton Dickinson and Co's market cap, and Becton Dickinson and Co pays the higher dividend (2.34%). Which is the better fit depends on your goals.
| AAPL | BDX | |
|---|---|---|
Market Cap | $4.50T | $48.93B |
Volume | 100,358,844 | — |
Sector | Technology | Health |
52-Week High | $340.08 | $185.39 |
52-Week Low | $224.90 | $138.62 |
Enterprise Value | $4.52T | $65.03B |
Dividend Yield | 0.35% | 2.34% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Apple's stock trades at $306.2, down 2.28% for the day, with a bearish technical signal and key support at $306. Fundamentally, the company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $2.02 exceeding the $1.89 estimate, and revenue growth to $416.16 billion in 2025. Recent news highlights institutional buying and AI potential through a partnership with Alphabet's Gemini.
The outlook remains positive with a consensus price target of $337.63, implying upside, supported by robust profitability and cash flow. Risks include weaker iPhone sales forecasts, union disputes, and high valuation multiples. Analyst sentiment is bullish with 63.64% buy ratings, but investors should monitor execution amid competitive and regulatory pressures.
BDX (Becton, Dickinson and Company) trades at $176.86, down 0.12% on the day, with a bullish technical outlook supported by moving averages and strong earnings beats in recent quarters. The company reported Q3 2026 revenue of $5.0 billion, up 4.4% FX-neutral, and raised full-year guidance, though margins faced pressure. Analyst sentiment is mixed with a consensus price target of $183.00, while institutional ownership remains stable amid positive news on GLP-1 therapy expansions and dividend declarations.
The stock offers steady growth potential with a 2.7% dividend yield and consistent earnings outperformance, but risks include margin compression, regulatory recalls, and high valuation multiples. Near-term resistance at $180 and support at $173 will test bullish momentum, with the current price near the consensus target suggesting limited upside without further catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Apple Inc
Apple Inc. designs, manufactures, and markets personal computers and related personal computing and mobile communication devices along with a variety of related software, services, peripherals, and networking solutions. Apple sells its products worldwide through its online stores, its retail stores, its direct sales force, third-party wholesalers, and resellers.
Read more on AAPL →About Becton Dickinson and Co
Becton, Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures diagnostic instruments and reagents, as well as flow cytometry and cell-imaging systems. BD Interventional (largely the former Bard business) accounts for 23% of revenue. International revenue accounts for 44% of the company's business.
Read more on BDX →
